(Q42547050)

2 November 2017

Urolithiasis associated with the protease inhibitor indinavir (English)

1 reference

2 November 2017

1 reference

1 reference

Bruce RG

1

1 reference

2 November 2017

Munch LC

2

1 reference

2 November 2017

Hoven AD

3

1 reference

2 November 2017

Jerauld RS

4

1 reference

2 November 2017

Greenburg R

5

1 reference

2 November 2017

Porter WH

6

1 reference

2 November 2017

Rutter PW

7

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

2 November 2017

1 reference

2 November 2017

50

1 reference

2 November 2017

4

1 reference

2 November 2017

513-518

1 reference

Protease inhibitors and urolithiasis

2 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900399-3

7 January 2021

Indinavir nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900399-3

7 January 2021

Triamterene and renal stone formation: the influence of triamterene and triamterene stones on calcium oxalate crystallization

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900399-3

7 January 2021

Triamterene stone: Advantage of crystallographic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900399-3

7 January 2021

10.1016/S0090-4295(97)00399-3

Identifiers

DOI

1 reference

2 November 2017

1 reference